| 苏尔云,陈辉树,韩月美.羚雄嘌呤散合龙蟾慈菇汤对急性髓系白血病缓解后的治疗观察[J].,2004,(2):124-126 |
| 羚雄嘌呤散合龙蟾慈菇汤对急性髓系白血病缓解后的治疗观察 |
| Observation on Treatment of Post-remission Acute Myeloid Leukemia Patients by Lingxiong Piaoling Powder and Longchan Cigu Decoction |
| |
| DOI： |
| 中文关键词: 急性髓系白血病 长期无病生存 羚雄嘌呤散 龙蟾慈姑汤 |
| 英文关键词:acute myeloid leukemia long-term disease-free survival Lingxiong Piaoling powder Longchan Cigu decoction |
| 基金项目: |
|
| Hits: 1755 |
| Download times: 1300 |
| 中文摘要: |
| 目的:探讨急性髓系白血病(acute myeloid leukemia,AML)缓解后长期生存的治疗方法。方法:29例AML完全缓解(CR)和17例部分缓解(PR)患者服用中药龙蟾慈菇汤每日1剂,羚雄嘌呤散每月7剂,DA(或HA)方案每年1个疗程。在治疗前后检测患者外周血象,骨髓涂片,骨髓活检及骨髓(human leuko-cyte antigen DR,HLA-DR)细胞。并随访患者的无病生存期(disease free survival,DFS)。结果:经本方案治疗后,外周血细胞计数恢复正常的人数明显增加(治疗前WBC≥4.0×109/L者为46％,Hb≥120g/L者为17％.PLT≥100×109/L者为63％;治疗2个月后分别为70％、46％及85％,P<0.05,P<0.01),骨髓有核细胞容量(vol％)明显增加(治疗前后分别为35.83±28.42、60.46±17.73,P<0.01);HLA-DR细胞也明显升高,治疗前后分别为[(10.55±4.95)％、(14.84±4.94)％,P<0.01];而残留白血病细胞1年来未见增加[治疗前为(5.90±5.09)％,治疗后为(5.82±2.42)％,P>0.05];患者最长DFS为123个月。3年生存率(64.15±1.96)％,5年生存率(51.19±16.25)％。结论:本研究的中西医结合治疗方案有利于延长AML完全缓解后患者的长期无病生存期。 |
| 英文摘要: |
| Objective: To explore the effect of the treatment for long-term disease-free survival (DFS) of post-remission patients with acute myeloid leukemia (AML). Methods: Twenty-nine AML patients with completely remission (CR) and 17 with partial remission (PR) were treated with Chinese medicine, Longchan Cigu Decoction 1 dose per day and Lingxiong Piaoling Powder 7 doses per month, and combined with DA or HA regimen of chemotherapy one course per year. Patients peripheral blood picture, bone marrow smear, biopsy and human leukocyte antigen DR (HLA-DR) cells were examined before and after treatment, and their disease-free survival (DFS) was followed up. Results: After treated with above mentioned treatment for 2 months, percentage of patients with normal peripheral blood count increased, including patients with WBC≥4.0×109/L raised from 46% to 70% , with Hb≥120g/L from 17% to 46% and with PLT≥100×109/L from 63% to 85% ; nucleated cell volume in bone marrow increased from 35.83±28.42 % to 60.46±17.73 % (P<0.01); HLA-DR cell was also increased significantly from 10.55±4.95% to 14.84 ±4.94 % , (P<0.01); while the residual leukemia cells were not increased in one year, from 5.90±5.09 % before and 5.82±2.42% after treatment (P>0.05). The maximal DFS in patients was 123 months. The 3-year survival rate was 64.15±1.96% and 5-year survival rate was 51.19±16.25% . Conclusion: The integrative Chinese and western medicine treating program used in this study is beneficial for the long-term treatment of AML patients after complete remission. |
| View Full Text View/Add Comment Download reader |
|
|
|
